This page uses content from Wikipedia and is licensed under CC BY-SA.

Revefenacin

Revefenacin
Revefenacin.svg
Clinical data
Trade namesYupelri
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC35H43N5O4
Molar mass597.760 g·mol−1
3D model (JSmol)

Revefenacin (trade name Yupelri) is a pharmaceutical drug for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018.[1] It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[2]

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.[3]

References

  1. ^ "Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease" (Press release). Mylan. November 9, 2018.
  2. ^ Heo, Young-A (2018). "Revefenacin: First Global Approval". Drugs. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.
  3. ^ Donohue, James; Kerwin, Edward; Barnes, Chris; Moran, Edmund; Haumann, Brett; Pendyala, Srikanth; Crater, Glenn (2018). "Efficacy of Revefenacin, A Long-Acting Muscarinic Antagonist for Nebulized Therapy, in Copd Patients with Markers of More Severe Disease". Chest. 154 (4): 736A–737A. doi:10.1016/j.chest.2018.08.665.